26
|
Gambardella V, Martinelli E, Tarazona N, Cervantes A. In the literature: July 2022. ESMO Open 2022; 7:100556. [PMID: 35961192 PMCID: PMC9434400 DOI: 10.1016/j.esmoop.2022.100556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2022] [Accepted: 07/04/2022] [Indexed: 11/20/2022] Open
|
27
|
Tarazona N, Gimeno-Valiente F, Cervantes A. Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible. ESMO Open 2022; 7:100547. [PMID: 35849878 PMCID: PMC9294252 DOI: 10.1016/j.esmoop.2022.100547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Accepted: 06/22/2022] [Indexed: 11/17/2022] Open
|
28
|
Ciardiello D, Roda D, Gambardella V, Cervantes A. In the literature: April 2022. ESMO Open 2022; 7:100479. [PMID: 35472677 PMCID: PMC9051610 DOI: 10.1016/j.esmoop.2022.100479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 03/22/2022] [Indexed: 11/16/2022] Open
|
29
|
Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. Ann Oncol 2022; 33:666. [PMID: 35365377 DOI: 10.1016/j.annonc.2022.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
30
|
Gambardella V, Cejalvo JM, González-Barrallo I, Gimeno-Valiente F, Cervantes A. In the literature: February 2022. ESMO Open 2022; 7:100411. [PMID: 35219243 PMCID: PMC8881704 DOI: 10.1016/j.esmoop.2022.100411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Accepted: 01/25/2022] [Indexed: 11/22/2022] Open
|
31
|
Martínez MT, Moragon S, Ortega-Morillo B, Montón-Bueno J, Simon S, Roselló S, Insa A, Viala A, Navarro J, Sanmartín A, Fluixá C, Julve A, Soriano D, Buch E, Peña A, Franco J, Martínez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme. Cancer Control 2022; 29:10732748221131000. [DOI: 10.1177/10732748221131000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Introduction The COVID-19 pandemic has disrupted many aspects of clinical practice in oncology, particularly regarding early cancer diagnosis, sparking public health concerns that possible delays could increase the proportion of patients diagnosed at advanced stages. In 2009, a cancer fast-track program (CFP) was implemented at the Clinico-Malvarrosa Health Department in Valencia, Spain with the aim of shortening waiting times between suspected cancer symptoms, diagnosis and therapy initiation. Objectives The study aimed to explore the effects of the COVID-19 pandemic on our cancer diagnosis fast-track program. Methods The program workflow (patients included and time periods) was analysed from the beginning of the state of alarm on March 16th, 2020 until March 15th, 2021. Data was compared with data from the same period of time from the year before (2019). Results During the pandemic year, 975 suspected cancer cases were submitted to the CFP. The number of submissions only decreased during times of highest COVID-19 incidence and stricter lockdown, and overall, referrals were slightly higher than in the previous 2 years. Cancer diagnosis was confirmed in 197 (24.1%) cases, among which 33% were urological, 23% breast, 16% gastrointestinal and 9% lung cancer. The median time from referral to specialist appointment was 13 days and diagnosis was reached at a median of 18 days. In confirmed cancer cases, treatment was started at around 30 days from time of diagnosis. In total, 61% of cancer disease was detected at early stage, 20% at locally advanced stage, and 19% at advanced stage, displaying time frames and case proportions similar to pre-pandemic years. Conclusions Our program has been able to maintain normal flow and efficacy despite the challenges of the current pandemic, and has proven a reliable tool to help primary care physicians referring suspected cancer patients.
Collapse
|
32
|
Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. In the literature: December 2021. ESMO Open 2021; 7:100352. [PMID: 34920292 PMCID: PMC8685987 DOI: 10.1016/j.esmoop.2021.100352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2021] [Accepted: 11/22/2021] [Indexed: 11/22/2022] Open
|
33
|
Gambardella V, Martínez-Ciarpaglini C, Fleitas T, Cervantes A. In the literature: October 2021. ESMO Open 2021; 6:100285. [PMID: 34752996 PMCID: PMC8586749 DOI: 10.1016/j.esmoop.2021.100285] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Accepted: 09/22/2021] [Indexed: 11/21/2022] Open
|
34
|
Yoshino T, Argilés G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti BK, Ahn JB, Faud I, Chee CE, Yeh KH, Lin PC, Chua C, Hasbullah HH, Lee MA, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol 2021; 32:1496-1510. [PMID: 34411693 DOI: 10.1016/j.annonc.2021.08.1752] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 08/02/2021] [Accepted: 08/05/2021] [Indexed: 12/24/2022] Open
Abstract
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of localised colon cancer was published in 2020. It was decided by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual guidelines meeting in March 2021 to adapt the ESMO 2020 guidelines to take into account the ethnic differences associated with the treatment of localised colon cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with localised colon cancer representing the oncological societies of Japan (JSMO), China (CSCO), India (ISMPO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug availability and reimbursement situations in the different Asian countries.
Collapse
|
35
|
Zapata O, Cervantes A, Barreras A, Monge-Navarro F, González-Vizcarra V, Estrada-Angulo A, Urías-Estrada J, Corona L, Zinn R, Martínez-Alvarez I, Plascencia A. Effects of single or combined supplementation of probiotics and prebiotics on ruminal fermentation, ruminal bacteria and total tract digestion in lambs. Small Rumin Res 2021. [DOI: 10.1016/j.smallrumres.2021.106538] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Gambardella V, Alfaro-Cervelló C, Cejalvo JM, Tapia M, Cervantes A. In the literature: August 2021. ESMO Open 2021; 6:100247. [PMID: 34411970 PMCID: PMC8377552 DOI: 10.1016/j.esmoop.2021.100247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2021] [Accepted: 07/27/2021] [Indexed: 11/20/2022] Open
|
37
|
Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, González-Farré B, Arance Fernandez A, Martin-Liberal J, Gavilá J, López González A, Cejalvo J, Izarzugaza Y, Amillano K, Garcia-Corbacho J, Saura Manich C, Salvador F, Pascual T, Mesía R, Cervantes A, Tabernero J. 1025TiP SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
38
|
Martinez M, Simón S, Montón-Bueno J, Moragón S, Morillo BO, Roselló S, Navarro J, Sanmartin A, Julve A, Flores M, Buch E, Peña A, Franco J, Martínez-Jabaloyas J, Marco J, Forner M, Cano A, Bermejo B, Cervantes A, Chirivella I. 1624P Impact of the COVID-19 pandemic in the cancer fast-track programme. Ann Oncol 2021. [PMCID: PMC8454345 DOI: 10.1016/j.annonc.2021.08.1617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
39
|
Tarazona N, Martín-Arana J, Tébar-Martínez R, Gimeno-Valiente F, Gambardella V, Alvaro MH, Martínez-Ciarpaglini C, Alfaro-Cervello C, Cabeza-Segura M, García-Micó B, Moragón S, Tapia M, Carbonell-Asins J, Rentero-Garrido P, Zuñiga S, Roselló S, Fleitas T, Castillo J, Perez DR, Cervantes A. 464P Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
40
|
Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia JL, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S. Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. ESMO Open 2021; 6:100237. [PMID: 34411971 PMCID: PMC8302832 DOI: 10.1016/j.esmoop.2021.100237] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Revised: 07/16/2021] [Accepted: 07/20/2021] [Indexed: 01/04/2023] Open
|
41
|
Dijkstra E, Hospers G, van de Velde C, Fleer J, Bahadoer R, Guren M, Tjalma J, Putter H, Meershoek-Klein Kranenbarg E, Roodvoets A, ten Tije A, Capdevila J, Hendriks M, Cervantes A, Nilsson P, Glimelius B, van Etten B, Marijnen C. OC-0337 Quality of life, functional outcome and late toxicity in patients treated within the RAPIDO trial. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06870-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
42
|
Wainberg Z, Matos I, Delord J, Cassier P, Gil-Martin M, Kim T, LoRusso P, Bahleda R, Italiano A, Mendus D, Hoang T, Xue C, Wen X, Carvalho O, Pham T, Patil N, Meng R, Bendell J, Cervantes A, Cho B. LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.06.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
43
|
Shah M, Yoshino T, Tebbutt N, Grothey A, Tabernero J, Xu R, Taieb J, Cervantes A, Oh S, Yamaguchi K, Fakih M, Falcone A, Wu C, Chiu V, Tomasek J, Bendell J, Fontaine M, Hitron M, Xu B, Van Cutsem E. O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
44
|
Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO pays tribute to Professor José Baselga. Ann Oncol 2021; 32:823-824. [PMID: 34090547 DOI: 10.1016/j.annonc.2021.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
45
|
Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. In the literature: June 2021. ESMO Open 2021; 6:100186. [PMID: 34098228 PMCID: PMC8190484 DOI: 10.1016/j.esmoop.2021.100186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2021] [Accepted: 05/18/2021] [Indexed: 11/12/2022] Open
|
46
|
Smyth EC, Gambardella V, Cervantes A, Fleitas T. Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Ann Oncol 2021; 32:1190-1191. [PMID: 34033882 DOI: 10.1016/j.annonc.2021.05.795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Accepted: 05/13/2021] [Indexed: 11/29/2022] Open
|
47
|
Martínez MT, Montón-Bueno J, Simon S, Ortega B, Moragon S, Roselló S, Insa A, Navarro J, Sanmartín A, Julve A, Buch E, Peña A, Franco J, Martínez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. ESMO Open 2021; 6:100148. [PMID: 33989988 PMCID: PMC8136438 DOI: 10.1016/j.esmoop.2021.100148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 04/12/2021] [Accepted: 04/13/2021] [Indexed: 11/07/2022] Open
Abstract
Background Cancer is the second leading cause of mortality worldwide. Integrating different levels of care by implementing screening programmes, extending diagnostic tools and applying therapeutic advances may increase survival. We implemented a cancer fast-track programme (CFP) to shorten the time between suspected cancer symptoms, diagnosis and therapy initiation. Patients and methods Descriptive data were collected from the 10 years since the CFP was implemented (2009-2019) at the Clinico-Malvarrosa Health Department in Valencia, Spain. General practitioners (GPs), an oncology coordinator and 11 specialists designed guidelines for GP patient referral to the CFP, including criteria for breast, digestive, gynaecological, lung, urological, dermatological, head and neck, and soft tissue cancers. Patients with enlarged lymph nodes and constitutional symptoms were also considered. On identifying patients with suspected cancer, GPs sent a case proposal to the oncology coordinator. If criteria were met, an appointment was quickly made with the patient. We analysed the timeline of each stage of the process. Results A total of 4493 suspected cancer cases were submitted to the CFP, of whom 4019 were seen by the corresponding specialist. Cancer was confirmed in 1098 (27.3%) patients: breast cancer in 33%, urological cancers in 22%, gastrointestinal cancer in 19% and lung cancer in 15%. The median time from submission to cancer testing was 11 days, and diagnosis was reached in a median of 19 days. Treatment was started at a median of 34 days from diagnosis. Conclusions The findings of this study show that the interval from GP patient referral to specialist testing, cancer diagnosis and start of therapy can be reduced. Implementation of the CFP enabled most patients to begin curative intended treatment, and required only minimal resources in our setting. Our CFP easily connects GPs and hospital specialists. Our CFP shortens assessment time in patients with suspected cancer, adding to quality care. Our CFP decreases emotional stress in patients without cancer.
Collapse
|
48
|
Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO pays tribute to Professor José Baselga. ESMO Open 2021. [PMID: 34144776 PMCID: PMC8233648 DOI: 10.1016/j.esmoop.2021.100130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
49
|
Martín-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo JM, Cervantes A. In the literature: April 2021. ESMO Open 2021; 6:100116. [PMID: 33887688 PMCID: PMC8086009 DOI: 10.1016/j.esmoop.2021.100116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 03/17/2021] [Indexed: 11/29/2022] Open
|
50
|
Cejalvo JM, Gambardella V, Fleitas T, Cervantes A. In the literature: February 2021. ESMO Open 2021; 6:100061. [PMID: 33639602 PMCID: PMC7921503 DOI: 10.1016/j.esmoop.2021.100061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Accepted: 01/20/2021] [Indexed: 11/26/2022] Open
|